Public Employees Retirement System of Ohio Has $6.81 Million Stock Position in Natera, Inc. $NTRA

Public Employees Retirement System of Ohio boosted its stake in Natera, Inc. (NASDAQ:NTRA) by 14.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,312 shares of the medical research company’s stock after acquiring an additional 5,052 shares during the period. Public Employees Retirement System of Ohio’s holdings in Natera were worth $6,810,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Guided Capital Wealth Management LLC boosted its stake in shares of Natera by 0.5% in the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock valued at $2,219,000 after purchasing an additional 66 shares during the last quarter. Fulton Bank N.A. boosted its position in Natera by 2.0% during the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company’s stock valued at $516,000 after acquiring an additional 71 shares during the last quarter. Wedmont Private Capital grew its holdings in Natera by 4.9% during the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock worth $256,000 after acquiring an additional 74 shares during the period. Compound Planning Inc. raised its position in shares of Natera by 4.2% in the 1st quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company’s stock worth $271,000 after acquiring an additional 78 shares in the last quarter. Finally, QRG Capital Management Inc. raised its position in shares of Natera by 1.5% in the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock worth $766,000 after acquiring an additional 81 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $162.97 on Monday. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $183.00. The company has a market capitalization of $22.37 billion, a PE ratio of -85.32 and a beta of 1.68. The business has a fifty day moving average price of $158.87 and a two-hundred day moving average price of $156.18.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm’s revenue was up 32.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In other Natera news, CFO Michael Burkes Brophy sold 3,045 shares of the firm’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total value of $418,383.00. Following the completion of the transaction, the chief financial officer directly owned 65,430 shares of the company’s stock, valued at $8,990,082. This trade represents a 4.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gail Boxer Marcus sold 4,299 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the transaction, the director owned 8,118 shares in the company, valued at approximately $1,358,628.48. This trade represents a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,423 shares of company stock valued at $8,459,656 in the last three months. Insiders own 5.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on NTRA shares. Stephens reaffirmed an “overweight” rating and set a $183.00 target price on shares of Natera in a research note on Friday, August 15th. Morgan Stanley reaffirmed an “overweight” rating and set a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 target price on the stock in a research report on Monday, July 28th. Wells Fargo & Company started coverage on shares of Natera in a report on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 price target for the company. Finally, Barclays restated an “overweight” rating and issued a $210.00 target price (up from $190.00) on shares of Natera in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $192.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.